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Progression through mitosis promotes PARP
inhibitor-induced cytotoxicity in homologous
recombination-deﬁcient cancer cells
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Mutations in homologous recombination (HR) genes BRCA1 and BRCA2 predispose to
tumorigenesis. HR-deﬁcient cancers are hypersensitive to Poly (ADP ribose)-polymerase
(PARP) inhibitors, but can acquire resistance and relapse. Mechanistic understanding how
PARP inhibition induces cytotoxicity in HR-deﬁcient cancer cells is incomplete. Here we ﬁnd
PARP inhibition to compromise replication fork stability in HR-deﬁcient cancer cells, leading
to mitotic DNA damage and consequent chromatin bridges and lagging chromosomes in
anaphase, frequently leading to cytokinesis failure, multinucleation and cell death.
PARP-inhibitor-induced multinucleated cells fail clonogenic outgrowth, and high percentages
of multinucleated cells are found in vivo in remnants of PARP inhibitor-treated Brca2 / ;
p53 / and Brca1 / ;p53 / mammary mouse tumours, suggesting that mitotic
progression promotes PARP-inhibitor-induced cell death. Indeed, enforced mitotic bypass
through EMI1 depletion abrogates PARP-inhibitor-induced cytotoxicity. These ﬁndings provide
insight into the cytotoxic effects of PARP inhibition, and point at combination therapies to
potentiate PARP inhibitor treatment of HR-deﬁcient tumours.
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RCA1 and BRCA2 function in the repair of DNA double-
strand breaks (DSBs) through homologous recombination
(HR), and ensure the protection of stalled replication
forks1. Defective HR is thought to underlie the progressive
accumulation of genomic aberrations, leading to malignant
transformation. Indeed, mutations in BRCA1 and BRCA2
predispose to tumorigenesis, most frequently involving breast
and ovarian cancer2–4. Due to their DNA repair defect, BRCA1/2
mutant cancer cells are more sensitive to platinum-based
chemotherapeutics, as observed in preclinical models and in
clinical studies5–7. In addition, BRCA1/2 mutant cancers were
found to be selectively sensitive to inhibition of the poly-
(ADP)ribose polymerase PARP1 (refs 7–9). Unfortunately,
however, BRCA1/2 mutant cancers can acquire resistance and
relapse10.
Mechanistically, PARP1 promotes the repair of non-toxic
single-strand DNA breaks11, which are converted into potentially
toxic DSBs during S-phase8,9. These DSBs depend on HR for
repair, and hence were suggested to cause cell death in
HR-defective cancer cells. However, the number of single-
strand DNA breaks were not found to be increased after
PARP1 depletion or PARP inhibition11–13, and the synthetic
lethal interaction between PARP inhibition and HR deﬁciency
may therefore involve other mechanisms14,15. Indeed, PARP1 and
BRCA1/2 were shown to orchestrate the protection and restart of
stalled replication forks16–20. Analogously, PARP1 activity
increases during replication21, and sensitivity to PARP
inhibition in BRCA2 mutant cancer cells can be rescued by
mutations that prevent replication fork degradation22.
Notably, aberrant replication intermediates may persist in
G2-phase, and can even be propagated into mitosis23–27, and
cause mitotic aberrancies28–30. Whether DNA lesions induced by
PARP inhibition in HR-deﬁcient cells persist into mitosis, and if
they affect cell division remains unclear.
Here, we study the mechanisms by which PARP-inhibitor-
induced DNA lesions affect mitotic progression. We describe that
PARP inhibition compromises replication fork stability and leads
to DNA lesions that are transmitted into mitosis. During mitosis,
these DNA lesions cause chromatin bridges and lead to
cytokinesis failure, multinucleation and cell death. Importantly,
our data show that progression through mitosis promotes PARP-
inhibitor-induced cell death, since forced mitotic bypass.
abrogates PARP-inhibitor-induced cytotoxicity.
Results
PARP-inhibitor-induced lesions are transmitted into mitosis.
To explore the consequences of PARP inhibition on mitotic
progression in HR-defective cancer cells, we depleted BRCA2 in
HeLa cells (Fig. 1a). As expected, treatment with the PARP
inhibitor olaparib resulted in selective killing of BRCA2-depleted
cells (Fig. 1b). In line with roles for BRCA2 and PARP in facil-
itating replication fork stability22, we observed compromised
replication fork protection using single DNA ﬁbre analysis upon
BRCA2 depletion, which was aggravated upon PARP inhibition
(Fig. 1c,d). These ﬁndings show that PARP inhibition in BRCA2-
deﬁcient cancer cells incrementally interferes with replication
fork stability. In line with previous studies showing involvement
of Mre11 and PTIP in degradation of stalled replication fork in
BRCA2-deﬁcient cells, Mre11 inhibition using mirin or PTIP
depletion alleviated the fork protection defects (Supplementary
Fig. 1A,B)20,22.
Defective replication fork stability upon PARP inhibition was
further underscored by the increase in FANCD2 foci in
interphase cells upon BRCA2 depletion. A signiﬁcant further
increase was observed when BRCA2-depleted cells were treated
with PARP inhibitor (Fig. 1e). Surprisingly, the increase in
FANCD2 foci was only accompanied by minor increases in the
numbers of g-H2AX foci in interphase, suggesting that replica-
tion lesions do not per se result in DNA breaks (Supplementary
Fig. 1C).
The observed replication lesions were not resolved before
mitotic entry, as increased numbers of FANCD2 foci were
observed in BRCA2-depleted mitotic cells (Fig. 1f). Again,
the numbers of FANCD2 foci increased further upon PARP
inhibitor treatment (Fig. 1f). Of note, in PARP inhibitor-treated,
BRCA2-depleted mitotic cells, numbers of g-H2AX foci were
increased similarly to FANCD2 foci (Supplementary Fig. 1D).
Combined, these data show that PARP inhibition in BRCA2-
defective cells leads to replication intermediates that are
transmitted into mitosis.
PARP inhibition causes mitotic chromatin bridges. Since
persistence of unresolved replication intermediates into mitosis
may interfere with proper chromosome segregation, we tested
whether PARP inhibition-induced mitotic aberrancies. Whereas
PARP inhibition did not affect the percentages of anaphase or
telophase cells containing chromatin bridges in control cells,
depletion of BRCA2 in HeLa cells led to an increased percentage
of cells showing chromatin bridge formation, which remained
unresolved up until telophase (14 and 17% in BRCA2-depleted
cells versus 2% in control-depleted cells) (Fig. 2a,b), in line with
previous observations31. Strikingly, the number of BRCA2-
depleted cells containing anaphase chromatin bridges markedly
increased upon olaparib treatment (59 and 65% in BRCA2-
depleted, olaparib-treated cells versus 20% in control-depleted
cells treated with olaparib) (Fig. 2a,b). Interestingly, whereas most
of the olaparib-induced chromatin bridges were resolved before
telophase in control cells, chromatin bridges persisted throughout
mitosis in BRCA2-depleted cells (49 and 57% in BRCA2-depleted
cells versus 6% in control-depleted cells) (Fig. 2b). Furthermore,
PARP inhibition also markedly increased the numbers of lagging
chromosomes in BRCA2-depleted cells (58 and 53% in BRCA2-
depleted cells versus 8% in control-depleted cells) (Fig. 2b, right
panel).
These observations were not speciﬁc for BRCA2, as depletion
of BRCA1 (Supplementary Fig. 2A,B) or RAD51 (Supplementary
Fig. 2C,D) also showed a clear induction of PARP-inhibitor-
induced chromatin bridges persisting throughout mitosis.
Notably, BRCA1 or RAD51 depletion in HeLa cells also increased
the amount of lagging chromosomes upon PARP inhibition,
although to a lesser extent in BRCA1-depleted cells when
compared to RAD51 or BRCA2-depleted cells (Fig. 2b, right
panel and Supplementary Fig. 2B,D, right panels). Similar results
were obtained upon depletion of BRCA1 or BRCA2 in BT-549
breast cancer cells treated with olaparib. Speciﬁcally, PARP
inhibitor sensitivity greatly increased upon doxycycline-induced
shRNAs depletion of BRCA1 or BRCA2 (Supplementary Fig. 2E,F).
Importantly, the numbers of unresolved chromosome bridges
(Fig. 2c), and lagging chromosomes (Supplementary Fig. 2G)
increased signiﬁcantly in BRCA1/2-depleted BT-549 cells upon
olaparib treatment.
We next investigated whether permanent genetic inactivation
of BRCA1 shows a similar increase in the amount of mitotic
chromatin bridges, when compared to acute siRNA-mediated
BRCA2/BRCA1 inactivation. Indeed, the human HCC1937 breast
cancer cell line, harbouring a BRCA1 deletion as well as a
hypomorphic BRCA1 allele with a 5382insC frameshift mutation,
showed increased chromatin bridges in anaphase and telophase
upon olaparib treatment (Fig. 2d), as well as lagging chromo-
somes (Supplementary Fig. 2H). To validate these results using
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15981
2 NATURE COMMUNICATIONS | 8:15981 | DOI: 10.1038/ncomms15981 | www.nature.com/naturecommunications
isogenic models, we next used a tumour cell line derived from a
K14cre;Brca2del/del;p53del/del mouse mammary tumour (denoted
as Brca2 / )32. As a control, we used an isogenic cell line in
which BRCA2 was reconstituted using an infectious bacterial
artiﬁcial chromosome (iBAC), harbouring the mouse Brca2 gene
(denoted as Brca2iBAC)33. Brca2iBAC expression functionally
restored BRCA2 function as judged by irradiation-induced foci
formation of RAD51 (Supplementary Fig. 3A),
and a rescue from PARP inhibitor sensitivity (Supplementary
Fig. 3B).
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Figure 1 | PARP-inhibitor-induced lesions are transmitted into mitosis. (a) Immunoblotting of BRCA2 and b-Actin at 48 h after transfection of indicated
siRNAs in HeLa cells. Lines next to blots indicate positions of molecular weight markers. (b) HeLa cells were transfected with indicated siRNAs for 24 h and
subsequently replated and treated with indicated olaparib concentrations for 72 h. Viability was assessed by MTT conversion. Shown graphs are
representative of three independent experiments, with three technical replicates each. P values were calculated using two-tailed Student’s t-test.
‘NS’ indicates not signiﬁcant. * indicates Po0.05, ** indicates Po0.01, *** indicates Po0.001. (c) HeLa cells were transfected with indicated siRNAs and
labelled with CldU as indicated. Cells were then treated with HU (5mM) and DMSO or olaparib (0.5mM) for 5 h. The DNA was spread into single ﬁbres
and CldU track length was determined (125 ﬁbres per condition). (d) Quantiﬁcation of ﬁbre lengths described in c. P values were calculated using two-tailed
Mann–Whitney test. (e,f) HeLa cells were transfected with siRNA targeting BRCA2 and treated with DMSO or olaparib (0.5mM) for 24 h. Cells were
stained for FANCD2 (green) and counterstained with DAPI (blue) and the number of FANCD2 foci per nuclei were quantiﬁed for interphase cells (e) and
mitotic cells (f). Per condition n¼ 100 nuclei were analysed. Indicated numbers between brackets represent (average—median) from three independent
experiments. P values were calculated using two-tailed Mann–Whitney test. Throughout the ﬁgure ‘NS’ indicates not signiﬁcant. All error bars indicate s.d.
of three independent experiments.
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Figure 2 | PARP inhibition causes mitotic chromatin bridges. Throughout the ﬁgure blue bars represent BRCA1/2 proﬁcient cells, red bars represent
BRCA1/2 deﬁcient cells, and P values were calculated using two-tailed Student’s t-test. (a) HeLa cells were transfected with indicated siRNAs and
immunoblotted for BRCA2 and b-Actin levels after 48 h. Lines next to blots indicate positions of molecular weight markers. In parallel, cells were treated
with DMSO or olaparib (0.5mM) for 24 h and stained for a-Tubulin (red) and counterstained with DAPI (white). Representative immunoﬂuorescence
images are presented. Scale bars represent 5 mm. (b) HeLa cells were treated as for a. The percentages of cells containing chromatin bridges (n420 events
per condition) and lagging chromosomes (n440 events per condition) were quantiﬁed. (c) BT-549 cells harbouring indicated shRNA vectors were pre-
treated with doxycycline for 48h and treated with olaparib (0.5 mM) or DMSO for 24 h. Percentages of cells containing chromatin bridges in anaphase and
telophase (n420 events per condition) were quantiﬁed. (d) HCC1937 cells were treated with olaparib (0.5mM) or DMSO for 24 h. Percentages of
anaphase (ana.) or telophase (telo.) cells containing chromatin bridges (n420 events per condition) were quantiﬁed. (e) KB2P1.21 (Brca2 / ) and
KB2P1.21R1 (Brca2iBac) cells were treated with olaparib (0.5 mM) or DMSO for 24 h. Percentages of anaphase or telophase cells containing chromatin
bridges (left panel, n420 events per condition) and cells containing lagging chromosomes (right panel, n440 events per condition) were quantiﬁed.
(f,g) HeLa cells were transfected with indicated siRNAs and after 24 h were treated with olaparib (0.5 mM) or DMSO and/or mirin (50 mM) for 24 h.
The percentages of anaphase or telophase cells containing chromatin bridges (n420 events per condition) were quantiﬁed. Throughout the ﬁgure ‘NS’
indicates not signiﬁcant and ‘NA’ indicates not analysable. All error bars indicate s.d. of three independent experiments.
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In accordance with our observations after transient BRCA2
depletion, PARP inhibition in Brca2 / cells resulted in an
increased percentage of cells harbouring chromatin bridges in
anaphase (71% in Brca2 / cells versus 17% in Brca2iBAC cells),
which to a large degree remained unresolved until telophase
(42% in Brca2 / cells versus 5% in Brca2iBAC cells) (Fig. 2e,
left panel). Again, also the percentage of cells with lagging
chromosomes was increased (39% versus 8% in Brca2 / and
Brca2iBAC cells, respectively) (Fig. 2e, right panel). These
observations again likely reﬂected generic consequences of
defective HR, as very similar defects were observed in a tumour
cell line derived from K14cre;Brca1F5-13/F5-13;p53F2-10/F2-10 mice
(Supplementary Fig. 3C). These observations were further
validated in DLD-1 human colorectal adenocarcinoma cells, in
which BRCA2 was inactivated using CRISPR-Cas9. In complete
accordance to what was observed in mouse Brca2-null cells,
BRCA2 / DLD-1 cells were sensitive to PARP inhibition
(Supplementary Fig. 3D), and PARP inhibition greatly enhanced
the formation of chromatin bridges as well as lagging chromo-
somes in BRCA2 / , but not in BRCA2þ /þ DLD-1 cells
(Supplementary Fig. 3E). Combined, these ﬁndings indicate that
PARP inhibition induces mitotic defects when HR is inactivated
acutely or permanently, in a species-independent fashion.
Since the formation of mitotic chromatin bridges and lagging
chromosomes in HR-deﬁcient cancer cells are a likely conse-
quence of disturbed replication fork integrity, we tested the
involvement of Mre11 and PTIP. Mre11 inhibition or PTIP
depletion, which alleviated the PARP-inhibitor-induced replica-
tion fork instability (Supplementary Fig. 1A,B), also reduced the
amounts of mitotic chromatin bridges (Fig. 2f,g). These ﬁndings
further corroborate that aberrant control of replication fork
stability underlies PARP-inhibitor-induced chromosome
bridge formation in mitosis. Notably, the amount of lagging
chromosomes was not reduced upon Mre11 or PTIP inactivation,
suggesting different biological origins of these lesion
(Supplementary Fig. 3F,G).
PARP trapping is required for chromatin bridge formation.
Cytotoxicity of PARP inhibitors was previously associated with
the ability of PARP inhibitor to trap PARP onto DNA, rather
than its effects on PARP catalytic activity15. To test whether
PARP trapping is required for the observed mitotic defects,
we depleted PARP1 using siRNA (Fig. 3a). In contrast to
treatment with olaparib, a PARP inhibitor which has trapping
activity, depletion of PARP1 did not signiﬁcantly induce mitotic
chromatin bridges, nor lagging chromosomes in BRCA2-depleted
cells (Fig. 3b and Supplementary Fig. 4A). Also, very similar levels
of mitotic chromatin bridges and lagging chromosomes were
observed in response to the structurally unrelated PARP inhibitor
AZD2461 (Fig. 3c,d and Supplementary Fig. 4B). Of note, the
observed increase in chromosome bridges in PARP inhibitor-
treated cells was much more pronounced when compared to
cisplatin treatment, at a dose that efﬁciently caused DNA breaks
as judged by g-H2AX (Fig. 3c,d).
Since PARP is involved in multiple cellular processes, we next
tested whether the PARP-inhibitor-induced mitotic defects
required treatment during S-phase. To this end, cells were
synchronized at the G1/S-phase of the cell cycle using a double-
thymidine block (Fig. 3e). Cells treated during S-phase displayed
signiﬁcantly increased numbers of mitotic cells with FANCD2
foci (Fig. 3f), chromosome bridges as well as lagging chromo-
somes (Fig. 3g). In line with expectations, BRCA2-depleted cells
with chromosome bridges also contained higher numbers of
mitotic FANCD2 foci, when compared to cells without chromo-
some bridges (Supplementary Fig. 4C). Importantly, when cells
were treated with olaparib past S-phase (at 7 h after release from
thymidine block), the number of FANCD2 foci in mitotic cells
(Fig. 3f), chromosome bridges as well as lagging chromosomes
(Fig. 3g) was signiﬁcantly reduced. Taken together, these data
show that PARP trapping during S-phase is required for
induction of mitotic chromosome bridges.
Chromatin bridges cause multinucleation and cell death.
Unresolved chromatin bridges can cause genomic aberrations,
multinucleation and cell death. To investigate the consequences
of PARP-inhibitor-induced chromatin bridges for HR-deﬁcient
cells, live-cell imaging was used in combination with stable
expression of ﬂuorescently tagged Histone-H2B to visualize
chromosome dynamics (Fig. 4a). Although some chromatin
bridge events were observed in DMSO-treated control cells, the
majority of mitoses proceeded either without any visible
chromatin bridges (cells with chromatin bridge: 24%) or with
chromatin bridges that were resolved during the course of mitosis
(6%) (Fig. 4b). Very comparable results were found for control-
depleted cells treated with PARP inhibitor (chromatin bridge:
32%; resolved bridge: 14%), or BRCA2-depleted cells treated with
DMSO (chromatin bridge: 26%; resolved bridge: 12%) (Fig. 4b).
In stark contrast, the amount of aberrant mitoses was strongly
increased in BRCA2-depleted cells treated with PARP inhibitor
(chromatin bridge: 64%; resolved bridge: 13%) (Fig. 4b and
Supplementary Fig. 5A). Furthermore, in a large fraction of
BRCA2-depleted cells, unresolved mitotic chromatin bridges
resulted in failed cytokinesis leading to multinucleation (29% of
total mitoses), or were followed by cell death, (22% of total
mitoses), indicating that mitotic failure following PARP inhibitor
treatment is often detrimental for BRCA2-deﬁcient cells (Fig. 4b
and Supplementary Fig. 5A).
Similar phenotypes were observed in Brca2-null mouse
mammary tumour cells, expressing GFP-tagged Histone-H2B
and mCherry-tagged a-Tubulin (Fig. 4c). Again, PARP inhibitor
treatment of Brca2-null mouse cells greatly enhanced the number
of cells with chromatin bridges (82% versus 22% in Brca2 /
and Brca2iBAC, respectively, Fig. 4c). Furthermore, most of the
chromatin bridges in Brca2 / cells were not resolved during
mitosis and lead to cytokinesis failure, accompanied with
multinucleation (32% versus 5% in Brca2 / and Brca2iBAC,
respectively), or cell death (16% versus 1% in Brca2 / and
Brca2iBAC, respectively) (Fig. 4c). These effects were not caused
by expression of GFP-HistoneH2B or mCherry-a-Tubulin, as
similar amounts of cells with 44n DNA content were observed
using ﬂow cytometry in BRCA2-depleted HeLa cells or Brca1/2-
null cells lacking these reporters (Fig. 4d–f, Supplementary
Fig. 5B–D). In conclusion, PARP inhibition in cells with
inactivated BRCA2 leads to chromatin bridges, which frequently
remain unresolved and are associated with multinucleation and
cell death.
As PARP inhibitor treatment resulted in a large fraction of
multinucleated cells upon cytokinesis failure, we wondered to
what extent these cells contribute to clonogenic survival. We
therefore sorted BRCA2-depleted cells based on DNA content
and separately plated cells with 2n, 4n and 44n DNA content
(Fig. 5a and Supplementary Fig. 6A–C). As expected, DMSO-
treated, BRCA2-depleted HeLa cells with either 2n or 4n DNA
content resulted in efﬁcient clonogenic outgrowth (Fig. 5b).
Similarly, 2n or 4n Brca2 / cells showed comparable numbers
of colonies (Fig. 5c). Notably, DMSO-treated cells with 44n
DNA content showed a B50% decrease in clonogenic potential,
indicating that multinucleation reduces viability, but does not
per se preclude long-term survival of tumour cells, in line
with previous reports34,35. Indeed, multinucleated cells did not
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display an intrinsic inability to replicate, as judged by BrdU
incorporation (Supplementary Fig. 6D,E). Importantly, upon
PARP inhibition, clonogenic survival was markedly decreased in
both BRCA2-depleted HeLa cells as well as Brca2 / cells, with
4n DNA-containing cells consistently showing a more
pronounced decrease in clonogenic outgrowth (Fig. 5b,c).
Notably, cells with 44n DNA content showed a near-complete
loss of colony formation, showing that PARP-induced
multinucleation precludes long-term viability in cells lacking
functional BRCA2.
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To test whether these observations could be extrapolated
in vivo, we analysed Brca2 / ;p53 / mammary tumours,
generated in K14cre;Brca2F/F;p53F/F mice, orthotopically trans-
planted into syngeneic wild-type (wt) mice, and treated with
vehicle or olaparib for 28 days (Fig. 5d). Notably, remnants of
olaparib-treated Brca2 / ;p53 / tumours showed signiﬁ-
cantly increased numbers of multinucleated cells (Fig. 5d,e).
To test if this phenotype is generic for HR-deﬁcient tumours, we
also analysed Brca1 / ;p53 / mammary tumours, derived
from K14cre;Brca1F/F;p53F/F mice (Fig. 5f). Again, tumour
remnants of olaparib-treated Brca1 / ;p53 / tumours
showed signiﬁcantly increased numbers of multinucleated cells
(Fig. 5f,g). Taken together, these data conﬁrm PARP-inhibitor-
induced multinucleation in BRCA1- or BRCA2-deﬁcient tumour
cells, and suggest that failed mitosis may contribute to the
cytotoxicity of PARP inhibition in these cancer cells.
Mitotic progression promotes PARP-inhibitor cytotoxicity. We
next investigated to what extent the progression through mitosis
contributes to the cytotoxic effects of PARP inhibitor treatment
in these tumour cells. To address this, we aimed to prevent
progression through mitosis, while still allowing for DNA repli-
cation. To this end, we inactivated the early mitotic inhibitor-1
(EMI1). During interphase, EMI1 keeps the APC/C E3 ligase
inactive, and thereby allows for the accumulation of numerous
mitotic regulators, including B-type cyclins36. Inactivation
of EMI1 leads to premature APC/C activation in G2-phase,
interferes with cyclin B accumulation and consequently precludes
mitotic entry. As a result, EMI1-depleted cells bypass mitosis
and enter cycles of endoreplication37. Indeed, following
EMI1 depletion, HeLa cells were unable to enter mitosis, yet
continued DNA replication as judged by a large population of
endoreplicating cells (44n DNA content) by ﬂow cytometry
(Fig. 6a,b). Subsequently, HeLa cells were depleted for BRCA2
either alone or in combination with EMI1, and induction of
apoptosis was analysed by annexin-V staining (Fig. 6c). Whereas
olaparib treatment resulted in clear induction of apoptosis in
BRCA2-depleted cells, co-depletion of EMI1 rescued the
induction of apoptosis (Fig. 6c,d). Next, we assessed whether
these effects translated into altered short-term cell survival.
Interestingly, olaparib sensitivity of BRCA2-depleted cells was
largely nulliﬁed by concomitant EMI1 depletion (Fig. 6e). These
observations were conﬁrmed in BRCA2 / DLD-1 cells, in
which PARP inhibitor sensitivity was rescued when mitosis was
bypassed due to EMI1 depletion (Fig. 6f,g). Importantly, EMI1
depletion did not alleviate induction of DNA lesions in response
to PARP inhibition in BRCA2-depleted cells, as judged by foci
analysis of FANCD2 (Supplementary Fig. 7A) and g-H2AX
(Supplementary Fig. 7B). Also, loss of PARP inhibitor sensitivity
could not be attributed to decreased proliferation rates, since EdU
incorporation was not impaired after BRCA2 and EMI1
co-depletion, when compared to depletion of BRCA2 alone.
(Supplementary Fig. 7C). Taken together, our data show that
forced bypass of mitosis results in decreased PARP inhibition-
induced cytotoxicity, and indicate that progression through
mitosis promotes cell death in BRCA2-deﬁcient cancer cells
treated with PARP inhibitor.
Discussion
Our ﬁndings on PARP-inhibitor-induced cytotoxicity in
HR-deﬁcient cancer cells extend on recent ﬁndings that mitotic
processing of DNA lesions is linked to genome stability24,25,38–40.
Further, our data challenge the dogma that accumulation of
DNA DSBs due to combined loss of base excision repair and HR
is the main contributor to synthetic lethality. While DSBs do
occur, other aberrant replication intermediates also arise
during replication in HR-deﬁcient cells treated with PARP
inhibitors23–27. Furthermore, our data show that these lesions
do not immediately lead to cell death, but can be transferred into
mitosis, resulting in chromatin bridging and subsequent
cytotoxicity. Inactivation of HR components BRCA1/2 or
RAD51 (ref. 31), or Fanconi Anemia components30, has been
previously linked to mitotic defects. Loss of either BRCA1/2 or
RAD51 was found to increase the percentage of cells with ultra-
ﬁne anaphase bridges as well as bulky chromatin bridges during
anaphase31, in agreement with our data. Previously, PARP
inhibition was shown to promote mitotic aberrancies and
multinucleation41. Similar to our data, these reports showed
that PARP inhibition alone does not appear to induce severe
effects on mitosis in wt cells. Rather, our data indicate that severe
mitotic defects only arise when PARP inhibitors are combined
with a HR defect.
Chromatin bridges were previously described to frequently
arise as a consequence of unresolved replication lesions26. Since
PARP inhibition in HR-deﬁcient cells also leads to replication
fork instability, it is conceivable that unresolved replication
intermediates underlie the formation of chromatin bridges in
HR-deﬁcient cells upon PARP inhibition. Although the exact
nature of these lesions remains obscure, the observed FANCD2-
positive foci in mitosis suggest that under-replicated regions may
persist after replication fork stalling. Indeed, secondary mutations
that rescue replication fork stability in BRCA2-deﬁcient cancer
cells, render them resistant to PARP inhibition22.
Late-stage replication intermediates that persist up until
mitosis are normally cleared by DNA resolvases40,42.
Speciﬁcally, the structure-speciﬁc endonuclease complex
MUS81-EME1 operates in conjunction with SLX4 and GEN1 to
resolve DNA joint molecules, and these enzymes are known to be
highly active during mitosis and are required for proper
chromosome segregation39,43. One could therefore speculate
Figure 3 | PARP trapping during S-phase is required for mitotic chromatin bridge formation. Throughout the ﬁgure blue bars represent BRCA1/2
proﬁcient cells, red bars represent BRCA1/2 deﬁcient cells. (a) HeLa cells were transfected with indicated siRNAs, and immunoblotting for BRCA2, PARP1
and b-Actin was done at 48 h after transfection. Lines next to blots indicate positions of molecular weight markers. (b) HeLa cells were transfected with
indicated siRNAs and after 24 h were treated with olaparib (0.5mM) or DMSO for 24 h. Percentages of cells containing chromatin bridges (n420 events
per condition) were quantiﬁed. P values were calculated using two-tailed Student’s t-test. (c) HeLa cells were transfected with indicated siRNAs, and after
24 h were treated with olaparib (0.5mM), AZD2461 (1mM), cisplatin (1mM) or DMSO for another 24 h. Immunoblotting was performed for BRCA2,
g-H2AX and b-Actin (d) HeLa cells were treated as for b. Percentages of cells containing chromatin bridges (n420 events per condition) were quantiﬁed.
P values were calculated using two-tailed Student’s t-test. (e–g) HeLa cells were transfected with indicated siRNAs and after 24 h were synchronized in the
G1/S-phase border by a double-thymidine block. Cells were either treated with 0.5 mM olaparib for 3 h directly after release from the thymidine block
(‘during S’ treatment) or 7 h after release (‘past S’ treatment). Representative ﬂow cytometry images are presented (e). Cells were then ﬁxed and assessed
for mitotic FANCD2 foci (f), chromatin bridges and lagging chromosomes (g). P values for FANCD2 foci were calculated using the two-tailed
Mann–Whitney test. The number of cells containing chromatin bridges (n420 events per condition) and lagging chromosomes (n440 events per
condition) were quantiﬁed. P values were calculated using two-tailed Student’s t-test. Throughout the ﬁgure ‘NS’ indicates not signiﬁcant. All error bars
indicate s.d. of three independent experiments.
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that the amount of DNA lesions induced by PARP inhibition in
HR-defective cells exceeds the resolvase capacity during mitosis,
and leads to the accumulation of toxic DNA lesions.
Interestingly, forced mitotic bypass through EMI1 depletion
could largely rescue viability of HR-deﬁcient cells upon PARP
inhibition. This implies that progression through mitosis
facilitates PARP-induced cytotoxicity, at least in short-term
assays. Since EMI1 is an essential gene in vivo44 and is also
required for long-term growth in vitro45–47, we do not consider
EMI1 downregulation as a clinically relevant means to achieve
long-term PARP inhibitor resistance. Rather, EMI1 served as a
tool to bypass mitosis without impairing replication. In line with
this notion, RNA sequencing analysis of Brca2 mutant cancers
that were either sensitive or resistant to PARP inhibition did not
provide evidence that EMI1 loss is involved in PARP inhibitor
resistance (Supplementary Fig. 7D).
In addition, our results suggest that PARP-inhibitor-induced
cytotoxicity requires cycles of both replication and mitosis, and
that tumour cells that remain in G1- or G2-phase longer are more
resistant to PARP-inhibitor-induced cytotoxicity. Conversely,
drugs that promote mitotic entry, such as WEE1 or DDR kinase
inhibitors, may potentiate PARP inhibitor treatment. Preliminary
evidence indeed shows additive effects of combined inhibition of
PARP and WEE1 in BRCA2-deﬁcient cells, which warrants
further investigation (Supplementary Fig. 8).
Alternatively, targeting the mitotic spindle using tubulin
poisons could be an interesting approach to potentiate PARP
inhibitor treatment in HR-deﬁcient cells. Further characterization
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24 h and subsequently treated with olaparib (0.5mM) for 24 h. Subsequently, cells were analysed by live-cell microscopy for 36 h. Representative YFP-H2B
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content are indicated. Averages and s.d. from three technical replicates are indicated. P values were calculated using two-tailed Student’s t-test. Throughout
the ﬁgure ‘NS’ indicates not signiﬁcant.
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of the nature of the DNA lesions that underlie mitotic chromatin
bridges and the pathways that respond to these structures is
required to elucidate how PARP inhibitor therapy functions at
the molecular and cellular level. These insights could then aid in
designing rational combination therapies to potentiate PARP
inhibitor treatment.
Methods
Cell culture and cell cycle synchronization. HeLa human cervical cancer cells,
HEK293T human embryonic kidney cells and human BT-549 and HCC1937 breast
cancer cell lines were obtained from ATCC (#CCL2, #CRL3216, #HTB122 and
#CRL2336 respectively). DLD-1 human colorectal adenocarcinoma cells were from
Horizon (Cambridge, UK). HeLa and DLD-1 cells were cultured in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM). BT-549 and HCC1937 cells were cultured in
RPMI medium. Media were supplemented with 10% fetal calf serum (FCS) and
cells were cultured at 37 C in a humidiﬁed incubator supplied with 5% CO2. The
KB2P1.21 cell line (denoted in the manuscript text as Brca2 / ) was established
from a mammary tumour from K14cre;Brca2F11/F11;p53F2-10/F2-10 mice and the
KB1P-B11 cell line (denoted in manuscript text as Brca1 / ) was established
from a mammary tumour from K14cre;Brca1F5-13/F5-13;p53F2-10/F2-10 mice7,48.
The KP3.33 cell line (denoted in the manuscript text as p53 / ) was established
from a mammary tumour from K14cre;p53F2-10/F2-10 mice32. The KB2P1.21R1 cell
line (denoted as Brca2iBAC) was generated through stable introduction of an iBAC
containing the entire mouse Brca2 gene into the KB2P1.21 cell line32. All mouse
cell lines were cultured in DMEM/F-12 medium, supplemented with 10% FCS,
50 units per ml penicillin, 50 mgml 1 streptomycin, 5 mgml 1 insulin (Sigma),
5 ngml 1 epidermal growth factor (Life Technologies) and 5 ngml 1 cholera
toxin (Gentaur), at 37 C under hypoxic conditions (1% O2, 5% CO2). Cell cycle
synchronization was achieved using a double-thymidine block. Speciﬁcally, cells
were treated with thymidine (2mM) for 17 h, washed twice with PBS and were
incubated in warm medium for 9 h. Subsequently, cells were again incubated in
thymidine for 17 h, washed with PBS and released in pre-warmed medium and
collected at indicated time points. For treatment of cells during S-phase, cells were
treated immediately following release from thymidine. For treatment after S-phase,
cells were treated at 7 h after release from thymidine.
Virus infection. VSV-G pseudotyped retroviral particles were produced as
described previously49. In short, HEK293T cells were transfected with 10 mg of
indicated pRetroX of pLKO vector, combined with 2.5 mg pMD/p and 7.5 mg pMDg
plasmids, expressing the gag/pol and envelop proteins, respectively. The
supernatant containing retrovirus was harvested at 48–72 h following transfection,
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Figure 5 | Multinucleated BRCA2-deﬁcient cells arising from failed chromatin bridge resolution after PARP inhibitor treatment are not viable.
(a,b) HeLa cells were transfected with siRNA targeting BRCA2 for 24 h and were then treated with olaparib (0.5mM) or DMSO for 72 h. Cells were then
incubated with Hoechst for 45min at 37 C, after which cells containing 2n, 4n or 44n were sorted as shown in a. Subsequently, cells were sorted at a
density of 5,000 cells per well in six-wells plates. After 7 days, colony formation was quantiﬁed. The graph shows averages and s.d.’s from three replicates.
P values were calculated using two-tailed Student’s t-test. (c) KB2P1.21 (Brca2 / ) cells were treated, sorted and stained as described for a and b.
After 7 days, colony formation was quantiﬁed. The graph shows means with error bars indicating s.d. of three replicates. P values are calculated using
two-tailed Student’s t-test. (d) H&E staining of a Brca2 / ;p53 / mammary tumour derived from a tumour-bearing mouse, treated with vehicle or
olaparib (50mg kg 1) for 21 days i.p. daily. Arrowheads indicate multinucleated cells. Scale bars represent 100 mm. (e) Quantiﬁcation of the percentage of
multinucleated cells in tumours described in d. (f) H&E staining of a Brca1 / ;p53 / tumour derived from a tumour-bearing mouse, treated
with vehicle or olaparib (50mg kg 1) for 21 days i.p. daily. Multinucleated cells and apoptotic cells are indicated. Scale bars represent 100mm.
(g) Quantiﬁcation of the percentage of multinucleated cells in tumours described in f. P values were calculated using two-tailed Student’s t-test.
Throughout the ﬁgure ‘NS’ indicates not signiﬁcant.
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Figure 6 | Mitotic progression promotes PARP-inhibitor cytotoxicity. (a) HeLa cells were transfected with indicated siRNAs, and immunoblotting for
BRCA2, EMI1 and b-Actin was performed at 48 h after transfection. Lines next to blots indicate positions of molecular weight markers. (b) HeLa cells were
transfected with indicated siRNAs for 48 h, and subsequently ﬁxed. DNA content was analysed by ﬂow cytometry. The percentage of cells containing44n
DNA is indicated. (c) HeLa cells were transfected with BRCA2 siRNAs or control siRNA (SCR), either alone or in combination with EMI1 siRNAs. After 24 h,
cells were replated and treated with olaparib (0.5mM) for 72 h, after which cells were stained with annexin-V-FITC and propidium iodide, and were
analysed by ﬂow cytometry. (d) HeLa cells were treated and analysed as for c. Averages and s.d. of three independent experiments are shown. P values
were calculated using two-tailed Student’s t-test. (e) HeLa cells were transfected with two independent BRCA2 siRNAs or control siRNA (SCR), either
alone or in combination with siRNAs targeting EMI1. After 24 h, cells were replated and allowed to attach for 3 h. Subsequently, cells were treated with
indicated concentrations of olaparib for 72 h, and viability was assessed by MTTconversion. Graphs are representative of three independent experiments,
and error bars indicate s.d. of three technical replicates. P values were calculated using two-tailed Student’s t-test. (f,g) DLD-1 wt or DLD-1 BRCA2 / cells
were transfected with two independent siRNAs targeting EMI1 or control siRNA (SCR). After 24 h, cells were replated and incubated for 3 h. Subsequently,
cell lysates were immunoblotted for BRCA2, EMI and b-Actin (f). In parallel, cells were treated with indicated concentrations of olaparib for 72 h, and
viability was assessed by MTTconversion (g). Graphs are representative of three independent experiments, and error bars indicate s.d. of three technical
replicates. P values were calculated using two-tailed Student’s t-test. Throughout the ﬁgure ‘NS’ indicates not signiﬁcant, * indicates Po0.05 and **
indicates Po0.01.
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was ﬁltered through a 0.45-mM syringe ﬁlter and was subsequently used to infect
target cells.
Establishment of HeLa cells stably expressing YFP-H2B cells was described
previously27. In short, HeLa cells were retrovirally infected with pBabe-H2B-YFP,
and selected with blasticidine (5 mgram ml 1, Sigma). To establish KB2P1.21 and
KB2P1.21R1 cell lines expressing H2B-EGFP and a-tubulin-mCherry, cells were
ﬁrst transduced with pRetrox-rTTa virus and selected with Geneticin
(400 mgml 1). Subsequently, cells were infected with a pRetrox-Tight-Pur virus
harbouring H2B-EGFP–T2A-a-tubulin-mCherry and selected in puromycin
(1mgml 1). H2B-EGFP and a-tubulin-mCherry expression was induced by
incubation with doxycycline (0.5 mgml 1, Sigma).
MTT assays. HeLa, DLD-1, BT-549, HCC1937, KB2P1.21 and KB2P1.21R1
tumour cell lines were plated in 96-wells plates. BT-549 cells were pre-treated with
1 mgml 1 doxycycline for 48 h. HeLa were plated at 2,000 cells per well, DLD-1
cells at 5,000 cells per well, BT-549 and HCC1937 cells at 1,000 cells per well, and
KB2P1.21 and KB2P1.21R1 were plated at 1,200 cells per well. Cells were allowed
to attach for 3 or 24 h and were treated with indicated concentrations of olaparib,
MK-1775, or MK4827 (all from Axon Medchem, Groningen, the Netherlands) for
3 or 4 days. Methyl-thiazol tetrazolium (MTT) was added to cells at a con-
centration of 5mgml 1 for 4 h, after which culture medium was removed and
formazan crystals were dissolved in DMSO. Absorbance values were determined
using a Bio-Rad benchmark III Biorad microtiter spectrophotometer at a wave-
length of 520 nm. Proliferation was determined as the relative decrease in signal
compared to DMSO-treated cells. Unless mentioned otherwise, statistical sig-
niﬁcance was tested using Student’s t-test.
RNA interference. Cells were transfected with 40 nM siRNAs (Ambion Stealth
RNAi, Thermoﬁsher) targeting BRCA2 (sequence 1: #HSS186121 and sequence 2:
sequence #HSS101095), BRCA1 (sequence 1: #HSS101089 and sequence 2:
#HSS186096), RAD51 (sequence HSS1299001), PARP1 (sequence 1: #HSS100243
and sequence 2: #HSS100244), PAXIP1 (encoding PTIP) (sequence #HSS117971),
EMI1 (sequence 1: #HSS119992 and sequence 2: #HSS119993) or a scrambled
(SCR) control sequence (sequence #12935300) with oligofectamine (Invitrogen) by
using manufacturer’s guidelines. Alternatively, cells were transduced with Tet-
pLKO-puro vectors, for doxycycline-inducible expression of shRNAs (Addgene
plasmid #219125, a kind gift from Dmitri Wiederschain50. The shRNA sequences
are: Luciferase (‘LUC’): 50-AGAGCTGTTTCTGAGGAGCC-30 , BRCA1: 50- CCC
TAAGTTTACTTCTCTAAA-30 and BRCA2: 50-AACAACAATTACGAACCAA
ACTT-30 . shRNAs were induced using 1 mgml 1 doxycycline (Sigma) for 48 h.
Western blotting. Cells were lysed using mammalian protein extraction reagent
(Thermo Scientiﬁc), supplemented with protease inhibitor and phosphatase
inhibitor cocktail (Thermo Scientiﬁc). Protein content was determined with a
Bradford assay after which 20 mg of protein sample was separated by sodium
dodecyl sulfate (SDS)/PAGE, transferred to polyvinylidene ﬂuoride (immobilon)
membranes and blocked in 5% skimmed milk (Sigma) in Tris-buffered saline
(TBS) containing 0.05% Tween20 (Sigma).
Immunodetection was performed with antibodies directed against BRCA2
(Calbiochem, #OP95), BRCA1 (Cell Signaling, #9010), RAD51 (GeneTex,
#gtx70230), EMI1 (Invitrogen, #37-6600), g-H2AX (Cell Signaling, #9718), PTIP
(Abcam, ab70434) all diluted 1:1,000 and Beta-Actin (MP Biomedicals, #69100)
diluted 1:10,000. Horseradish peroxidase-conjugated secondary antibodies
(DAKO) were diluted 1:2,500 and used for visualization using chemiluminescence
(Lumi-Light, Roche Diagnostics) on a Bio-Rad bioluminescence device, equipped
with Quantity One/ChemiDoc XRS software (Bio-Rad). Uncropped versions of all
western blots can be found in Supplementary Fig. 9.
Flow cytometry. For apoptosis analysis by annexin V staining, total cell popula-
tions were collected by trypsinization and stained with annexin-V-FITC (1:20) and
propidium iodide as per manufacturer’s instructions (Immune Quality Products).
Cells were then analysed on a LSR-II (Becton Dickinson) cytometer using
FACSDiva software (Becton Dickinson). For cell cycle analysis, BrdU and phos-
pho-HistoneH3 analysis, cells were ﬁxed in ice-cold 70% ethanol or methanol for at
least 6 h and were then immunostained with an Alexa-488-conjugated antibody
targeting BrdU (MoBU1, #B35130, 1:200), or anti-phospho-histone-H3 (Ser10, Cell
Signaling, #9701, 1:300) in combination with Alexa-488-conjugated secondary
antibodies (1:300). DNA staining was performed using propidium iodide in the
presence of RNAse. At least 10,000 events per sample were analysed on a
FACScalibur (Becton Dickinson). Data was analysed using FlowJo software.
Immunoﬂuorescence microscopy. HeLa, KB2P1.21 and KB2P21R1 cells were
seeded on glass coverslips in six-well plates. When indicated, HeLa cells were
transfected with siRNAs for 48 h or were treated with olaparib (0.5 mM) for 24 h as
indicated. If indicated, KB2P1.21 and KB2P21R1 cells were irradiated (5Gy) using
a CIS International/IBL 637 caesium137 source (dose rate: 0.010124Gy s 1). Cells
were ﬁxed using 4% formaldehyde or paraformaldehyde in PBS, and subsequently
permeabilized for 5min in PBS with 0.1% Triton X-100. After extensive washing,
cells were stained with antibodies targeting a-Tubulin (Cell Signaling, #2125,
1:100), RAD51 (GeneTex, #gtx70230, 1:400), FANCD2 (SantaCruz Biotechnology,
#sc20022, 1:200) or g-H2AX (Cell Signaling, #9718, 1:200), in combination with
Alexa-488 or Alexa-647-conjugated secondary antibodies (1:300), and were
counterstained with DAPI. Early anaphases in which chromosome packs were
separated less than 10 nm were excluded for analysis. Anaphase and telophase cells
were distinguished based on a-Tubulin staining. Images were acquired on a Leica
DM6000B microscope using a  63 immersion objective (PL S-APO, numerical
aperture: 1.30) with LAS-AF software (Leica).
Live-cell microscopy. KB2P2.21 and KB2P2.21R1 transduced with H2B-EGFP-
IRES-a-tubulin-mCherry and HeLa cells transduced with H2B-EGFP were seeded
in eight-chambered cover glass plates (Lab-Tek-II, Nunc) at 10,000 cells per well.
Cells were then treated with 0.5 mM olaparib at 24 h before imaging, and were
followed for at least 36 h on a DeltaVision Elite microscope, equipped with a
CoolSNAP HQ2 camera and a  40 immersion objective (U-APO 340, numerical
aperture: 1.35). Images were obtained each 10min, with 12 images being acquired
in the Z-axis, at 0.5 mm interval. Image analysis was done using SoftWorX software
(Applied Precision/GE Healthcare). The fate of all cells that entered mitosis and
proceeded at least until anaphase were included for analysis.
DNA ﬁbre analysis. To assess replication fork protection. HeLa cells were pulse-
labelled with CIdU (25 mM) for 60min. Next, cells were washed with medium and
incubated with hydroxyurea (HU, 5mM) for 5 h. Cells were harvested using
trypsine and lysed on microscopy slides in lysis buffer (0.5% SDS, 200mM Tris
(pH 7.4), 50mM EDTA). DNA ﬁbres were spread by tilting the slide and were
subsequently air dried and ﬁxed in methanol/acetic acid (3:1) for 10min. For
immunolabelling, spreads were treated with 2.5M HCl for 1.5 h. CIdU was
detected by staining with rat anti-BrdU (1:1,000, AbD Serotec) for 1 h and was
further incubated with AlexaFluor 488-conjugated anti-rat IgG (1:500) for 1.5 h.
Images were acquired on a Leica DM-6000RXA ﬂuorescence microscope, equipped
with Leica Application Suite software. The lengths of CIdU and IdU tracks were
measured blindly using ImageJ software. Statistical analysis was performed using
two-sided Mann–Whitney tests with 95% conﬁdence intervals.
Generation of mammary tumours. Brca1 / ;p53 / and Brca2 / ;p53 /
mammary tumours were generated in K14cre;Brca1F/F;p53F/F and K14cre;Brca2F/F;
p53F/F mice, respectively, genotyped, and orthotopically transplanted into syn-
geneic wt mice as described7. Starting 2 weeks after tumour grafting, in female
FVB/N mice (6–8 weeks old), the onset of tumour growth was checked at least
three times per week. Mammary tumour size was determined by caliper
measurements. When mammary tumours reached a size of B200mm3, treatment
was initiated. Olaparib was used by diluting 50mg per ml stocks in DMSO with
10% 2-hydroxyl-propyl-b-cyclodextrine/PBS such that the ﬁnal volume
administered by intraperitoneally (i.p.) injection was 10 ml g 1 of body weight.
Olaparib (50mg kg 1) was given i.p. daily for 21 or 28 consecutive days. Controls
were dosed with vehicle only. Animals were killed with CO2 at the end of treatment
when the minimal residual disease stage was reached. At this point, olaparib-
treated tumour explants had an approximate size of 1mm3, whereas control-
treated tumour explants had a volume of B1 cm3. Tumour samples were ﬁxed in
4% formaline and processed for hematoxylin/eosin staining. S.d. represent 10
different ﬁelds, containing at least 100 cells. All experimental procedures on
animals were approved by the Animal Ethics Committee of the Netherlands Cancer
Institute.
RNA sequencing and analysis. Fresh-frozen tumour tissues of AZD2461-sensi-
tive (n¼ 23) and AZD2461-resistant (n¼ 36) Brca2 / ;p53 / tumours
(described in (ref. 22)), were placed in 1ml of TRIsure reagent (Bioline) and
subjected to mechanical disruption with Tissue Lyser LT (Qiagen, oscillation:
50 s 1, time: 10min). Homogenized lysates were further processed for RNA
isolation following TRIsure manufacturer’s protocol. Quality and quantity of the
total RNA was assessed by the 2100 Bioanalyzer using a Nano chip (Agilent,
Santa Clara, CA). Total RNA samples having RIN48 were subjected to library
generation.
Strand-speciﬁc libraries were generated using the TruSeq Stranded mRNA
sample preparation kit (Illumina Inc., San Diego, RS-122-2101/2), according to the
manufacturer’s instructions (Illumina, Part #15031047 Rev. E). Brieﬂy,
polyadenylated RNA from intact total RNA was puriﬁed using oligo-dT beads.
Following puriﬁcation, the RNA was fragmented, random primed and reverse
transcribed using SuperScript II Reverse Transcriptase (Invitrogen, part #18064-
014) with the addition of Actinomycin D. Second strand synthesis was performed
using Polymerase I and RNaseH with replacement of dTTP for dUTP. The
generated cDNA fragments were 30-end adenylated and ligated to Illumina Paired-
end sequencing adapters and subsequently ampliﬁed by 12 cycles of polymerase
chain reaction. The libraries were analysed on a 2100 Bioanalyzer using a 7500 chip
(Agilent, Santa Clara, CA), diluted and pooled equimolar into a 10 nM sequencing
stock solution. Illumina TruSeq mRNA libraries were sequenced with 50 base
single reads on a HiSeq2000 using V3 chemistry (Illumina Inc., San Diego).
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The resulting reads were trimmed using Cutadapt (version 1.12)8 to remove any
remaining adapter sequences, ﬁltering reads shorter than 20 bp after trimming
to ensure efﬁcient mapping. The trimmed reads were aligned to the GRCm38
reference genome using STAR (version 2.5.2b)9. QC statistics from Fastqc
(version 0.11.5) and the above-mentioned tools were collected and summarized
using Multiqc (version 0.8)51. Gene expression counts were generated by
featureCounts (version 1.5.0-post3)52, using gene deﬁnitions from Ensembl
GRCm38 version 76. Normalized expression values were obtained by correcting for
differences in sequencing depth between samples using DESeq median-of-ratios
approach53, and subsequent log-transformation the normalized counts.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request. RNA sequence data has
been deposited at the European Nucleotide Archive (ENA) under accession
number PRJEB20535.
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